And yet another blow for an Ionis CNS antisense drug candidate….
Following the announcement last October of Phase 3 failure of tofersen in adults with ALS associated with a SOD1 mutation, Biogen and Ionis have suffered another disappointment in the ALS pipeline after BIIB078 (IONIS-C9Rx) failed to demonstrate clinical benefit in a 106 patient Phase 1 trial. BIIB078 is an investigational antisense therapy for the treatment of C9orf72-associated ALS.
No consistent difference was seen between the 60mg cohort and placebo and the 90mg cohort showed a greater decline on secondary endpoints than placebo.
https://www.prnewswire.com/news-rel...-amyotrophic-lateral-sclerosis-301511359.html
https://www.fiercebiotech.com/biote...t-quits-als-med-after-it-flunks-phase-1-trial
https://pharmaphorum.com/news/new-b...ogen-and-ionis-candidate-fails-phase-1-trial/
Ann: Retina Target Engagement Confirmed in Large Eye, page-84
Add PYC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.0¢ |
Change
-0.005(4.35%) |
Mkt cap ! $513.2M | |||
| Open | High | Low | Value | Volume |
| 11.5¢ | 11.8¢ | 11.0¢ | $297.5K | 2.621M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 1372418 | 11.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.5¢ | 390472 | 6 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| PYC (ASX) Chart |